2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-143744
    Suraxavir marboxil 2364589-86-4 98%
    Suraxavir marboxil (GP681; Cap-dependent endonuclease-IN-3) is a PA subunit cap-dependent endonuclease inhibitor with antiviral activity. Suraxavir marboxil inhibits PA subunit cap-dependent endonuclease activity and inhibits influenza A and/or influenza B viral replication. Suraxavir marboxil can be used alone or in combination with other anti-influenzal agents for the prevention of influenza A and/or influenza B viral infectious diseases. Suraxavir marboxil can be used for the research of influenza A and/or influenza B viral infectious diseases.
    Suraxavir marboxil
  • HY-143747
    Cap-dependent endonuclease-IN-5 2416258-53-0 98%
    Cap-dependent endonuclease-IN-5 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-5 inhibits influenza virus well, and/or has lower cytotoxicity, better in vivo pharmacokinetic properties and in vivo pharmacodynamic properties (extracted from patent WO2020078401A1, compound 13-1).
    Cap-dependent endonuclease-IN-5
  • HY-143749
    Cap-dependent endonuclease-IN-6 2489248-15-7 98%
    Cap-dependent endonuclease-IN-6 (compound 13) is a cap-dependent endonuclease (CEN) inhibitor. Cap-dependent endonuclease-IN-6 shows inhibition against influenza virus (EC50=38.21 nM).
    Cap-dependent endonuclease-IN-6
  • HY-143750
    Cap-dependent endonuclease-IN-7 2485715-97-5 98%
    Cap-dependent endonuclease-IN-7 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-7 Inhibits the synthesis of viral mRNA and eventually inhibits virus proliferation. Cap-dependent endonuclease-IN-7 has the potential for the research of viral infections (including influenza A, influenza B and influenza C) (extracted from patent WO2020177715A1, compound 5)
    Cap-dependent endonuclease-IN-7
  • HY-143752
    Cap-dependent endonuclease-IN-8 2454680-16-9 98%
    Cap-dependent endonuclease-IN-8 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-8 inhibits replication of orthomyxoviruses (including influenza A, influenza B and influenza C) (extracted from patent CN111410661A, compound I-196).
    Cap-dependent endonuclease-IN-8
  • HY-143755
    Cap-dependent endonuclease-IN-9 2631005-84-8 98%
    Cap-dependent endonuclease-IN-9 is a potent inhibitor of cap-dependent endonuclease (CEN). Not only can Cap-dependent endonuclease-IN-9 inhibit influenza virus well, but also has lower cytotoxicity, better in vivo agent kinetic properties and in vivo pharmacodynamic properties. Cap-dependent endonuclease-IN-9 has strong inhibitory effect on RNA polymerase activity of A virus (extracted from patent CN112521386A, compound VI-1).
    Cap-dependent endonuclease-IN-9
  • HY-143757
    Cap-dependent endonuclease-IN-10 2663989-04-4 98%
    Cap-dependent endonuclease-IN-10 is a potent inhibitor of cap-dependent endonuclease (CEN). Not only can Cap-dependent endonuclease-IN-10 inhibit influenza virus well, but also has lower cytotoxicity, better in vivo pharmacokinetic and in vivo pharmacodynamic properties, and better hepatic microsomal stability. Cap-dependent endonuclease-IN-10 has the potential for the research of viral infections (including influenza A, influenza B and influenza C) (extracted from patent WO2021129799A1, compound 1-1).
    Cap-dependent endonuclease-IN-10
  • HY-143762
    Cap-dependent endonuclease-IN-12 2460686-97-7 98%
    Cap-dependent endonuclease-IN-12 (EXP-35) is a potent Cap-dependent endonuclease inhibitor with low cytotoxicity. Cap-dependent endonuclease-IN-12 shows inhibitory activity against H1N1.
    Cap-dependent endonuclease-IN-12
  • HY-143766
    Cap-dependent endonuclease-IN-13 2703046-60-8 98%
    Cap-dependent endonuclease-IN-13 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-13 has the potential for the research of influenza virus infection (only influenza A) (extracted from patent WO2021180147A1, compound I-1).
    Cap-dependent endonuclease-IN-13
  • HY-143768
    Cap-dependent endonuclease-IN-14 2740486-73-9 98%
    Cap-dependent endonuclease-IN-14 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-14 inhibits the replication of influenza virus. Cap-dependent endonuclease-IN-14 has the potential for the research of viral infections caused by influenza viruses (extracted from patent CN113620948A, compound 1-c).
    Cap-dependent endonuclease-IN-14
  • HY-143769
    Sebaloxavir marboxil 2581298-44-2 98%
    Sebaloxavir marboxil (Cap-dependent endonuclease-IN-15) (Compound c-1) is a potent inhibitor of cap-dependent endonuclease (CEN). Sebaloxavir marboxil inhibits the replication of influenza virus. Sebaloxavir marboxil has the potential for the research of viral infections caused by influenza viruses.
    Sebaloxavir marboxil
  • HY-143770
    Cap-dependent endonuclease-IN-16 2643370-92-5 98%
    Cap-dependent endonuclease-IN-16 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-16 is a pyridone polycyclic derivative. Cap-dependent endonuclease-IN-16 has the potential for the research of influenza (extracted from patent CN112778330A, compound 15A).
    Cap-dependent endonuclease-IN-16
  • HY-143771
    Cap-dependent endonuclease-IN-17 2649362-71-8 98%
    Cap-dependent endonuclease-IN-17 is a cap-dependent endonuclease (CEN) inhibitor. Cap-dependent endonuclease-IN-17 shows antiviral activity against influenza virus A/Hanfang/359/95 (H3N2) with IC50 of 1.29 μM (CN112898346A; DSC701).
    Cap-dependent endonuclease-IN-17
  • HY-143775
    Cap-dependent endonuclease-IN-20 2656435-01-5 98%
    Cap-dependent endonuclease-IN-20 is a cap-dependent endonuclease (CEN) inhibitor. Cap-dependent endonuclease-IN-20 shows antiviral activity against influenza virus A/Hanfang/359/95 (H3N2) with IC50 of 4.82 μM (CN112940009A; DSC801).
    Cap-dependent endonuclease-IN-20
  • HY-143776
    Cap-dependent endonuclease-IN-22 2641942-32-5 98%
    Cap-dependent endonuclease-IN-22 is a potent cap-dependent endonuclease (CEN) inhibitor.
    Cap-dependent endonuclease-IN-22
  • HY-143781
    Cap-dependent endonuclease-IN-26 1370238-26-8 98%
    Cap-dependent endonuclease-IN-26 is a cap-dependent endonuclease (CEN) inhibitor with an IC50 of 286 nM. Cap-dependent endonuclease-IN-26 shows antiviral activity against many influenza A and B strains.
    Cap-dependent endonuclease-IN-26
  • HY-144019
    18:0 EPC chloride 328268-13-9 98%
    18:0 EPC chloride is a synthetic cationic phospholipid. 18:0 EPC chloride (at the critical synergistic concentrations of 2.34-2.93 μM) significantly improves the inactivation effect of eugenol against Escherichia coli.
    18:0 EPC chloride
  • HY-144045
    HBV-IN-14 2712529-19-4 98%
    HBV-IN-14 is a potent inhibitor of covalently closed circular DNA (cccDNA). cccDNA serves as the template for viral RNA transcription and subsequent viral DNA generation. HBV-IN-14 is a pyridinopyrimidinones compound. HBV-IN-14 has the potential for the research of HBV infection (extracted from patent WO2021190502A1, compound 5).
    HBV-IN-14
  • HY-144046
    HBV-IN-15 2413192-50-2 98%
    HBV-IN-15 is a potent inhibitor of covalently closed circular DNA (cccDNA). cccDNA serves as the template for viral RNA transcription and subsequent viral DNA generation. HBV-IN-15 is a flavone derivative. HBV-IN-16 has the potential for the research of HBV infection (extracted from patent WO2020052774A1, compound 2).
    HBV-IN-15
  • HY-144047
    HBV-IN-16 2355225-38-4 98%
    HBV-IN-16 is a potent inhibitor of covalently closed circular DNA (cccDNA). cccDNA serves as the template for viral RNA transcription and subsequent viral DNA generation. HBV-IN-16 is a quinoline derivative. HBV-IN-16 has the potential for the research of HBV infection (extracted from patent WO2019121357A1, compound 1).
    HBV-IN-16
Cat. No. Product Name / Synonyms Application Reactivity